Overview: HLA-B8 Typing TestIntroduction: The HLA-B8 Typing Test detects HLA-B8 antigen to assess transplant or autoimmune disease risk, aiding compatibility. Aligned with 2023 ASHI guidelines, it uses PCR for high specificity, supporting transplant screening. This test is critical for guiding transplant decisions, evaluating autoimmune risks, and improving outcomes in molecular pathology for patients undergoing transplantation or with HLA-related autoimmune conditions.
Other Names: HLA-B8 Assay, HLA-B8 Antigen Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: HLA typing began in the 1960s with transplant immunology. PCR-based HLA-B8 typing improved in the 2000s, enhancing autoimmune and transplant assessment.
Purpose: Assesses HLA-B8 for transplant compatibility, guides organ matching, and evaluates autoimmune disease risk in patients.
Test Parameters: 1. HLA-B8 Antigen
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva at any time. Report history of transplants, autoimmune diseases, or family history of HLA-related conditions.
Specimen: 2-5 mL whole blood (EDTA), 1-2 buccal swabs (sterile swab), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document history of transplants, autoimmune diseases, or family history of HLA-related conditions. Include current medications and prior transplant history.
Consent: Written consent required, detailing the tests purpose, compatibility implications, and potential need for transplant or autoimmune therapy.
Procedural Considerations: Uses PCR to detect HLA-B8 antigen. Results are available in 1-2 days, enabling rapid clinical decisions. Performed in laboratories, often for transplant or autoimmune assessment.
Factors Affecting Result Accuracy: Improper sample handling or contamination can affect results. Low DNA quality may impact typing accuracy.
Clinical Significance: Positive HLA-B8 indicates compatibility or autoimmune risk (e.g., celiac disease), guiding transplant or treatment decisions. Negative results may require alternative HLA typing.
Specialist Consultation: Consult a transplant immunologist or rheumatologist for result interpretation and planning.
Additional Supporting Tests: HLA-DR, anti-tTG antibodies, or antibody screening to assess transplant or autoimmune compatibility.
Test Limitations: Limited to HLA-B8; other HLA loci may need testing. Clinical correlation is needed.
References: ASHI HLA Guidelines, 2023; Human Immunology, Tait BD, 2022.
